HDAC2 and chronic myelogenous leukemia, BCR-ABL1 positive: To further investigate the mechanism behind this finding, we used HDAC1 and HDAC2 as a model to demonstrate the anticancer activity by HDACi drugs both with or without imatinib-resistant CML cells.